secwatch.observer — SEC 8-K summary
======================================

Issuer:     BAXTER INTERNATIONAL INC (BAX)
CIK:        0000010456
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001628280-23-036194
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Baxter Q3 2023 adjusted EPS $0.68 from continuing ops beats guidance; completes $4.25B BPS divestiture
--------------------------------------------------------------------------------

- Q3 revenue from continuing ops $3.71B (+3% reported, +2% CC), ahead of company guidance.
- GAAP EPS from continuing ops $0.09; adjusted EPS $0.68, exceeded prior guidance.
- Completed BioPharma Solutions divestiture for $4.25B; cash proceeds $3.96B; gain $2.89B; debt repayment use.
- Kidney Care spinoff on track to close by July 2024.
- FY 2023 adjusted EPS guidance $2.57-$2.60; Q4 2023 adjusted EPS guidance $0.85-$0.88.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10456/000162828023036194/0001628280-23-036194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10456/000162828023036194/bax-20231102.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-036194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer